ATE361068T1 - Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma - Google Patents

Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma

Info

Publication number
ATE361068T1
ATE361068T1 AT02751356T AT02751356T ATE361068T1 AT E361068 T1 ATE361068 T1 AT E361068T1 AT 02751356 T AT02751356 T AT 02751356T AT 02751356 T AT02751356 T AT 02751356T AT E361068 T1 ATE361068 T1 AT E361068T1
Authority
AT
Austria
Prior art keywords
plasma
removal
active substance
protein population
undesirable protein
Prior art date
Application number
AT02751356T
Other languages
English (en)
Inventor
Mark B Pepys
Original Assignee
Pentraxin Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0119370.5A external-priority patent/GB0119370D0/en
Application filed by Pentraxin Therapeutics Ltd filed Critical Pentraxin Therapeutics Ltd
Application granted granted Critical
Publication of ATE361068T1 publication Critical patent/ATE361068T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
AT02751356T 2001-08-08 2002-07-29 Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma ATE361068T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119370.5A GB0119370D0 (en) 2001-08-08 2001-08-08 Therapeutic agent
US09/985,699 US7045499B2 (en) 2001-08-08 2001-11-05 Therapeutic agent

Publications (1)

Publication Number Publication Date
ATE361068T1 true ATE361068T1 (de) 2007-05-15

Family

ID=26246416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751356T ATE361068T1 (de) 2001-08-08 2002-07-29 Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma

Country Status (8)

Country Link
US (2) US7691897B2 (de)
EP (1) EP1418905B1 (de)
JP (1) JP4472333B2 (de)
AT (1) ATE361068T1 (de)
DE (1) DE60219926T2 (de)
DK (1) DK1418905T3 (de)
ES (1) ES2284895T3 (de)
WO (1) WO2003013508A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390795B2 (en) 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
ATE361068T1 (de) 2001-08-08 2007-05-15 Pentraxin Therapeutics Ltd Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
GB0313386D0 (en) * 2003-06-10 2003-07-16 Univ London Treatment of disease
AU2008232254A1 (en) * 2007-03-23 2008-10-02 The Governors Of The University Of Alberta Multivalent heterobifunctional polymers and methods of their use
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
US9886546B2 (en) 2012-11-20 2018-02-06 General Electric Company Methods and apparatus to label radiology images
JP6964298B2 (ja) * 2016-06-29 2021-11-10 ザ スクリプス リサーチ インスティテュート ジプロボシム：新規かつ強力なクラスのｔｌｒアゴニスト
AU2019315952A1 (en) * 2018-08-02 2021-03-04 The Board Of Regents Of The University Of Texas System Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease
GB202014589D0 (en) 2020-09-16 2020-10-28 Ucl Business Ltd Agents for use in the treatment of amyloidosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277352A (ja) 1986-01-30 1987-12-02 Ono Pharmaceut Co Ltd 新規な６−ケト−プロスタグランジンｅ１誘導体、それらの製造方法およびそれらを有効成分として含有する細胞障害治療剤
US4895872A (en) 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
JPH0667472B2 (ja) * 1988-11-28 1994-08-31 鐘淵化学工業株式会社 血清アミロイドｐ蛋白用吸着体
DK1060750T3 (da) * 1993-03-29 2006-01-09 Univ Kingston Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose
GB9317120D0 (en) 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6534495B1 (en) 1997-05-02 2003-03-18 Akzo Nebel Serine protease inhibitors
US6365570B1 (en) 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
SI0915088T1 (en) * 1997-10-31 2002-12-31 F. Hoffmann-La Roche Ag D-proline derivatives
GB0119370D0 (en) * 2001-08-08 2001-10-03 Univ London Therapeutic agent
ATE361068T1 (de) 2001-08-08 2007-05-15 Pentraxin Therapeutics Ltd Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease

Also Published As

Publication number Publication date
US7691897B2 (en) 2010-04-06
US20060122124A1 (en) 2006-06-08
DE60219926D1 (de) 2007-06-14
DK1418905T3 (da) 2007-09-10
WO2003013508A1 (en) 2003-02-20
DE60219926T2 (de) 2007-11-22
US8173694B2 (en) 2012-05-08
JP2005501071A (ja) 2005-01-13
EP1418905A1 (de) 2004-05-19
ES2284895T3 (es) 2007-11-16
JP4472333B2 (ja) 2010-06-02
EP1418905B1 (de) 2007-05-02
US20100173969A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
AU2002243879A1 (en) Integrated blood handling system having active gas removal system and methods of use
DE60212663D1 (de) Dermales system zur wirkstoffabgabe
DE60043305D1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
PL371736A1 (en) Method for administering glp-1 molecules
DE60239554D1 (de) Medizinische vorrichtung zur abgabe von pflastern
TR200002965T2 (tr) Enfeksiyonların terapötik ve profilaktik tedavisi için organofosforlu terkiplerin kullanımı
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60132089D1 (de) Vorrichtung zur behandlung von gasen miitels plasma
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
ATE361068T1 (de) Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE481104T1 (de) Mittel zur behandlung von flaviviridae- infektionen
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
DE50108409D1 (de) Behandlung von oberflächen zur temporären verbesserung des schmutzablöseverhaltens
DE69817379D1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1418905

Country of ref document: EP

REN Ceased due to non-payment of the annual fee